CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls

European Neuropsychopharmacology

Volumn 20, Issue 1, 2010, Pages 18-24

  Moreno, Francisco A ^a   Parkinson, Damian ^a   Palmer, Craig ^a   Castro, Wm Lesley ^a   Misiaszek, John ^a   El Khoury, Aram ^b   Mathé, Aleksander A ^b   Wright, Ron ^a   Delgado, Pedro L ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cerebrospinal fluid (CSF); Monoamine metabolites; Neuropeptide Y; Sum of large neutral amino acids ( LNAA); Tryptophan depletion

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO ACID; NEUROPEPTIDE Y; PAROXETINE; TRYPTOPHAN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPLETION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REMISSION;

ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROCHEMISTRY; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INDOLES; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NEUROCHEMISTRY; NEUROPEPTIDE Y; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN; YOUNG ADULT;

EID: 71549120694     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.10.003     Document Type: Article

References (35)

1. Arborelius L., Owens M.J., Plotsky P.M., and Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160 1 (1999) 1-12
2. Agren H., Mefford I.N., Rudorfer M.V., Linnoila M., and Potter W.Z. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatr. Res. 20 3 (1986) 175-193
3. Carpenter L.L., Anderson G.M., Pelton G.H., Gudin J.A., Kirwin P.D., Price L.H., Heninger G.R., and McDougle C.J. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 19 (1998) 26-35
4. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., and Heninger G.R. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 47 (1990) 411-418
5. Delgado P.L., Price L.H., Aghajanian G.K., Miller H.M., Salomon R.M., Heninger G.R., and Charney D.S. Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry 51 (1994) 865-874
6. Delgado P.L., Miller H.M., Salomon R.M., Licinio J., Krystal J.H., Moreno F.A., Heninger G.R., and Charney D.S. Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Journal of Biological Psychiatry 46 (1999) 212-220
7. Dinan T.G. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci. 58 (1996) 1683-1694
8. Fri C.G., Winsel F.A., and Sedval G. Simultaneous quantification of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid by mass fragmentography. Life Sci. 14 (1974) 2469-2480
9. Gerhardt G.A., Drebing C.J., and Fredman R. The simultaneous determination of free Homovanillic acid, (3-methoxy-4-hydrxyphenyl) glycol, and vanilmandelic acid in human plasma by high-performance liquid chromatography coupled with dual-electrode coulometric electrochemical detection. Anal. Chem. 58 13 (1986) 2879-2883
10. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959) 51-53
11. Husum H., and Mathé A.A. Early life stress changes concentrations of Neuropeptide Y and Corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27 (2002) 756-764
12. Husum H., Van Kammen D., Termeer E., Bolwig T., and Mathé A.A. Topiramate normalizes hippocampal NPY-LI in Flinders Sensitive Line "Depressed" rats and upregulates NPY, galanin, and CRH in the hypothalamus. Implications for mood-stabilizing and weight-loss inducing effects. Neuropsychopharmacology 28 (2003) 1292-1299
13. Jiménez-Vasquez P.A., Mathé A.A., Thomas J.D., Riley E.P., and Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Dev. Brain Res. 131 (2001) 149-152
14. Kopin I.J., Jimerson D.C., Markey S.P., Ebert M.H., and Polinsky R.J. Disposition and metabolism of MHPG in humans: application to studies in depression. Pharmacopsychiatry 17 (1984) 3-8
15. Krstulovic A.M., Friedman M.J., Colin H., Guiochon G., Gaspar M., and Pajer K.A. Analytical methodology for assays of serum tryptophan metabolites in control subjects and newly abstinent alcoholics: preliminary investigation by liquid chromatography with amperometric detection. J. Chromatogr. 297 (1984) 271-281
16. Mathé A.A. Neuropeptides and Electroconvulsive Treatment. In: Lerer B., and Kellner C. (Eds). J. ECT vol. 15 (1999) 60-75
17. Mathé A.A., Rudorfer M.V., Stenfors C., Manji H.K., Potter W.C., and Theodorsson E. Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin and neurokinin A concentrations in cerebrospinal fluid of depressed patients. Depression 3 (1996) 250
18. Mazure C.M., Nelson J.C., and Price L.H. Reliability and validity of the symptoms of major depressive illness. Arch. Gen. Psychiatry 43 (1986) 451-456
19. Mitchell A.J. The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci. Biobehav. Rev. 22 (1998) 635-651
20. Moja E.A., Cipollo P., Castoldi D., and Tofanetti O. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci. 44 (1989) 971-976
21. Moreno F.A., Gelenberg A.J., Heninger G.R., Potter R.L., McKnight K., Allen J., Phillips A.P., and Delgado P.L. Tryptophan depletion and depressive vulnerability. Biol. Psychiatry 46 (1999) 498-505
22. Moreno F.A., McGavin C., Malan Jr. T.P., Gelenberg A.J., Heninger G.R., Mathé A.A., and Delgado P.L. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from a single lumbar puncture sampling technique. IJNP 3 (2000) 277-283
23. Moreno F.A., Heninger G.R., McGahuey C.A., and Delgado P.L. Tryptophan depletion and risk of depression relapse: a prospective study of TRP depletion as a potential predictor of depressive episodes. J. Biol. Psychiatry 48 4 (2000) 327-329
24. Moreno F.A., Rowe D.C., Kaiser B., Chase D., Michaels T., Gelernter J., and Delgado P.L. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol. Psychiatry 7 2 (2002) 213-216
25. Nemeroff C.B., Widerlöv E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., and Vale W. Elevated concentrations of corticotropin releasing factor-like immunoreactivity in depressed patients. Science 226 (1984) 1342-1344
26. Neumeister A., Yuan P., Young T.A., Luckenbaugh D.A., Charney D.S., and Manji H. Effects of tryptophan depletion on serum levels of brain derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am. J. Psychiatry 162 (2005) 805-807
27. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., Blier P., and Diksec M. Differences between males and females in rates of serotonin synthesis in human brain. Proc. Natl Acad. Sci. USA 94 (1997) 5308-5313
28. Pitchot W., Herrera C., and Ansseau M. HPA axis dysfunction in major depression: relationship to 5-HT (1A) receptor activity. Neuropsychobiology 44 (2001) 74-77
29. Salomon R.M., Kennedy J.S., Johnson B.W., Schmidt D.E., Kwentus J., Gwirtsman H.E., and Ebert M.H. Association of critical CSF tryptophan threshold level with depressive relapse. Neuropsychopharmacology 28 5 (2003) 956-960
30. Spitzer R.L. Structured Clinical Interview for DSM III-R. Biometrics Research Department (1987), New York State Psychiatric Institute, New York
31. Tyrka A.R., Carpenter L.L., McDougle C.J., Kirwin P.D., Owens M.J., Nemeroff C.B., Strong D.R., and Price L.H. Increased cerebrospinal fluid corticotrophin releasing factor concentrations during tryptophan depletion in healthy adults. Biol. Psychiatry 7 (2004) 531-534
32. Virkkunen M., Nuutila A., Goodwin F.K., and Linnoila M. Cerebrospinal fluid monoamine metabolite levels in male arsonist. Arch. Gen. Psychiatry 44 (1987) 241-247
33. Williams W.A., Shoaf S.E., Hommer D., Rawlings R., and Linnoila M.I. Effects of acute tryptophan depletion on plasma and cerobrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J. Neurochem. 72 4 (1999) 1641-1647
34. Woods S.W., Charney D.S., Goodman W.K., and Heninger G.R. Carbon dioxide induced anxiety. Arch. Gen. Psychiatry 45 (1988) 43-52
35. Young S.N., Ervin F.R., Pihl R.O., and Finn P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology 98 4 (1989) 508-511